Clinical Trials Logo

Recurrent Glioma clinical trials

View clinical trials related to Recurrent Glioma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05297864 Terminated - Clinical trials for Recurrent Glioblastoma

PARP Inhibition for Gliomas (PI-4G or π4g)

OU-SCC-PI-4G
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

NCT ID: NCT01324635 Terminated - Brain Metastasis Clinical Trials

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Start date: May 2012
Phase: Phase 1
Study type: Interventional

This is an open label phase I clinical trial with two arms, representing single and fractionated radiation therapy (Figure 4.1). Within each arm the radiation dose is pre-determined and not escalated. Panobinostat will be administered orally 3 times a week for 2 weeks. Panobinostat will be dose-escalated independently in each arm. There is no intra-patient dose escalation. Recurrent gliomas (Arm A) will be treated according to the Jefferson protocol for re-irradiation, 10 fractions each of 3.5Gy delivered over 2 weeks. Panobinostat will be administered orally three times a week for 2 weeks, starting on day 1 or 2 of radiation therapy. High-grade meningiomas (Arm A) will be treated with 6 weeks/30 fractions of fractionated radiation therapy, to a total dose of between 54 Gy and 60 Gy in fractions of either 1.8Gy or 2Gy. Panobinostat will be administered orally three times a week for 2 weeks, starting on the day of 1st fraction of radiation. Large brain metastases (Arm B) will be treated with a single fraction of radiosurgery. Panobinostat will be administered orally three times a week for 2 weeks, starting on the day of radiation. The radiosurgery may be delivered by either LINAC, gamma-knife, cyber-knife or tomotherapy technology.